www.fdanews.com/articles/113462-genta-summarizes-phase-2-activity-receives-orphan-drug-designation
Genta Summarizes Phase 2 Activity, Receives Orphan Drug Designation
January 5, 2009
Genta Incorporated announced that the Company has received notice from the U.S. Food and Drug Administration (FDA) that tesetaxel, the latest addition to Genta’s oncology product portfolio, has been granted designation as an “Orphan Drug” for treatment of patients with advanced gastric cancer.
centredaily.com
centredaily.com